TriSalus today said it appointed Trevor McCaw as chief commercial officer.

The chief commercial officer position is new within TriSalus, and McCaw will report directly to CEO Mary Szela. He will be responsible for integrating the company’s therapeutics and innovative drug delivery systems to provide a total solution for patients.

Prior to joining the company, McCaw was president and chief commercial officer of Clerio Vision. He has also served as president and chief operating officer for Blueprint Clinical.

“Trevor’s passion for taking on scientific challenges and translating them into solutions that make a difference in the lives of patients is inspiring. He shares our belief in the capabilities of integrating novel therapeutics with drug delivery systems in an effort to improve outcomes for patients with solid pancreatic and liver tumors. His talents solidify our management team and his experience and the results he’s achieved as a medical device leader will serve to advance the TriSalus vision. I’m excited by and confident in Trevor’s abilities to help us realize our vision on behalf of patients,” Szela said in a news release.

McCaw will also be the lead on the company’s on-market technology commercialization efforts, oversight of strategic and tactical execution of sales, upstream and downstream marketing, field clinical support and training and overusing of the long-term strategy for integrating therapeutics with TriSalus’s technology.

“My life’s work has been centered on advancing innovative medical device and healthcare technologies aimed at improving patients’ lives. I’m thrilled to be part of the TriSalus team and its belief in and willingness to develop ways to change the outcomes for those with the most intractable forms of cancer, namely solid tumors of the liver and the pancreas. Integrating novel therapeutics and device technology is such a logical, but underappreciated way in which we can make a difference in cancer care,” McCaw said.